Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy
- 20 February 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 27 (4), 635-643
- https://doi.org/10.1097/qad.0b013e32835cba6c
Abstract
Objective: To determine whether incident AIDS-defining Kaposi sarcoma or Pneumocystis jiroveci pneumonia (PJP) is associated with combination antiretroviral therapy (cART) initiation. Design: Compare risk for Kaposi sarcoma and PJP by time on cART and CD4 reconstitution. Methods: In the FHDH-ANRS CO4 cohort (N = 66 369), Kaposi sarcoma (N = 1811) and PJP (N = 1718) incidence rates were computed by demographic and HIV strata. Crude and adjusted relative risk (RR) with 95% confidence intervals (CIs) following cART initiation were calculated by Poisson regression with untreated patients during 1996–2009 as reference. CD4 cell counts were compared by Wilcoxon rank sum tests. Results: The risk of Kaposi sarcoma was very high during months 1–3 on cART (N = 160, RRCrude 3.94, 95% CI 3.26–4.76), which was incompletely attenuated by adjustment for demographics and contemporaneous CD4 cell count (RRAdj 1.25, 95% CI 1.02–1.53). Corresponding PJP risk was minimally elevated (N = 84, RRCrude 1.80, 95% CI 1.42–2.30) and markedly reduced with adjustment on the same variables and PJP prophylaxis (RRAdj 0.52, CI 0.41–0.67). HIV load had no added effect. Median CD4 cell count at cART initiation was much lower in patients with incident Kaposi sarcoma (82 cells/μl) or PJP (61 cells/μl) within 3 months than in those who did not develop these conditions (>250 cells/μl). Notably, median CD4 cell count change was +44 cells/μl per month with incident Kaposi sarcoma within 3 months of cART initiation versus 0 cells/μl per month with incident PJP (P = 0.0003). Conclusion: Failure of CD4 cell count reconstitution during months 1–3 on cART fully accounted for incident PJP. In contrast, there were 1.6 additional Kaposi sarcoma cases per 1000 person-years during months 1–3 on cART, suggesting that immune reconstitution may contribute to the risk for AIDS-defining Kaposi sarcoma.This publication has 30 references indexed in Scilit:
- Selective expansion of polyfunctional pathogen-specific CD4+ T cells in HIV-1–infected patients with immune reconstitution inflammatory syndromeBlood, 2012
- Immune restoration disease after antiretroviral therapyAIDS, 2004
- Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcomaAIDS, 2003
- Baseline Predictors of CD4 T-Lymphocyte Recovery With Combination Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Trends in Kaposi's Sarcoma and Non-Hodgkin's Lymphoma Incidence in the United States From 1973 Through 1998JNCI Journal of the National Cancer Institute, 2002
- Immune Reconstitution Inflammatory SyndromeMedicine, 2002
- Evidence for Concurrent Epidemics of Human Herpesvirus 8 and Human Immunodeficiency Virus Type 1 in US Homosexual Men: Rates, Risk Factors, and Relationship to Kaposi's SarcomaThe Journal of Infectious Diseases, 1999
- Population HIV‐1 Dynamics In Vivo: Applicable Models and Inferential Tools for Virological Data from AIDS Clinical TrialsBiometrics, 1999
- Kaposi's Sarcoma (KS), KS-associated Herpesvirus, and the Criteria for Causality in the Age of Molecular BiologyAmerican Journal of Epidemiology, 1998
- Expanded European AIDS case definitionThe Lancet, 1993